Featured

CTX001, an investigational gene-editing cell therapy, has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of severe sickle cell disease (SCD). The announcement was made by CRISPR Therapeutics and Vertex Pharmaceuticals, which are jointly…

As large parts of the world prepare for a second wave of coronavirus cases governments have pinned their hopes on the rapid development of a vaccine to provide a route…

Our August 2020 newsletter has just been published! Read about our latest updates, including country activities, international projects, educational updates for patients with thalassaemia and haemoglobin disorders, and our novel…

About 25 million blood transfusions are administered to patients every year throughout the European Union. What may come to mind to most people when thinking about blood transfusion is acute…

AstraZeneca Plc and the University of Oxford have resumed the British clinical trials of its Covid-19 vaccine, after the initial suspension over concerns with a participant who fell ill. University…

The Turkish Federation of Blood Diseases, Kan Hastalıkları Federasyonu  is joining forces with TIF for the organisation of the ”International Blood Diseases Virtual Symposium”, which will be held virtually on…

Tune in with TIF on Tuesday, 15 September 2020, 15:00 EEST, for one of the last webinars from the TIF eThalED series for Healthcare Professionals! The topic to be brought…

The pharmaceutical company AstraZeneca halted large, late-stage global trials of its coronavirus vaccine on Tuesday, because of a serious suspected adverse reaction in a participant. It is not yet known…

AstraZeneca Plc has begun final-stage, Phase III trial of its coronavirus vaccine AZD1222 in the U.S., according to the company´s latest statement. Trial centers across the US are recruiting up to 30,000 adults aged 18 years…